A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.
Cody J PeerOliver M HallTristan M SissungRichard PiekarzSanjeeve BalasubramaniamSusan E BatesWilliam D FiggPublished in: Cancer chemotherapy and pharmacology (2018)
This model suggests a q3week schedule allows for sufficient platelet recovery before the next belinostat infusion is optimal.